Partial
Partially Aligned
Patient Risk:
Low
Summary
Some high-level statements (indications and mechanism) are generally consistent with the label excerpts, but most claims about trial duration/percentages, real-world findings, and reasons for long-term effectiveness are not verifiable from the provided labeling text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is used for moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported by label excerpts in 1 INDICATIONS AND USAGE: 1.1 Plaque Psoriasis (moderate to severe in adults and pediatric ≥6), 1.2 Psoriatic Arthritis, and 1.3 Ankylosing Spondylitis (active).
Cosentyx’s effects persist due to its ability to target and block the IL-17 pathway.
Partially supported by mechanism excerpt 12.1 Mechanism of Action: secukinumab selectively binds IL-17A and inhibits interaction with IL-17 receptor. (Causal wording about persistence is not directly supported.)
The IL-17 pathway plays a central role in the inflammation and immune system dysregulation characteristic of these conditions.
Not explicitly supported in the provided excerpts; only mechanism (IL-17A binding/inhibition) is stated in 12.1. Central-role disease statement is not verifiable from provided label text.
Unsupported Statements
Clinical trials show that Cosentyx maintains effectiveness in treating plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis with long-term use.
Provided label excerpts include that clinical studies exist, but the prompt’s specific text does not provide long-term effectiveness statements for these conditions (e.g., duration-specific maintenance claims).
In clinical trials, response rates for Cosentyx remain stable over 3 to 5 years or more.
No response-rate stability over 3–5 years is provided in the supplied label excerpts.
In a Phase III study, over 80% of patients experienced sustained clinical response after 2 to 3 years with Cosentyx.
No numeric trial result (e.g., >80% sustained response at 2–3 years) appears in the supplied label excerpts.
Some patients still showed positive effects even after stopping Cosentyx in a Phase III study.
No label excerpt provided describing effects after discontinuation in Phase III studies.
Similar results have been observed in long-term studies involving patients with psoriatic arthritis treated with Cosentyx.
No provided excerpt contains long-term PsA result summaries.
Cosentyx’s long-term effectiveness can be influenced by patient adherence to treatment.
No label excerpt provided addresses adherence as a driver of long-term effectiveness.
Cosentyx’s long-term effectiveness can be influenced by underlying health conditions.
No label excerpt provided ties underlying health conditions to long-term effectiveness (beyond general population-specific statements, which were not included for this claim).
Cosentyx’s long-term effectiveness can be influenced by immunogenicity (the body’s immune response to the medication).
The label excerpt includes immunogenicity (12.6), but it does not provide a specific causal statement that immunogenicity influences long-term effectiveness.
Real-world studies using electronic health records support that Cosentyx’s benefits can persist for several years in some patients.
No real-world/electronic health record evidence is provided in the supplied label excerpts.
Real-world studies suggest Cosentyx benefits often exceed the typical duration of clinical trials.
No real-world comparative duration statements are provided in the supplied label excerpts.
Contradictions
Important Omissions
For the indication statement, the label excerpt specifies pediatric age thresholds (Psoriasis ≥6 years; PsA ≥2 years; AS ≥12 years). The AI claim did not mention any age qualification.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated are primarily efficacy/duration/real-world statements without dosing changes or safety-risk directives. However, unsupported long-term/percentage/discontinuation assertions could misinform about effectiveness expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most efficacy-duration, numeric, discontinuation, adherence/underlying conditions/immunogenicity causality, and real-world EHR longevity claims are not supported by the supplied label excerpts.
Suggested Improvement
Restrict statements to label-supported assertions: indications (with pediatric age thresholds) and mechanism of action (IL-17A binding/inhibition). Avoid specific time-frames, percentages, discontinuation effects, and real-world evidence unless those exact data are present in the provided label text.